Resumen
Los síntomas por disfunción autonómica son comunes en la enfermedad de Parkinson y están presentes en todas las fases de la enfermedad. Cubren una amplia variedad de síntomas, como manifestaciones gastrointestinales, urinarias, disfunción eréctil e hipotensión ortostática, entre otros, lo que genera discapacidad y deterioro en la calidad de vida. Afortunadamente, con intervenciones no farmacológicas y farmacológicas estos síntomas pueden mejorar sustancialmente, por lo que su evaluación resulta vital para el bienestar del paciente.
Citas
Ziemssen T, Reichmann H. Non-motor dysfunction in Parkinson's disease. Parkinsonism Relat Disord. 2007;13(6):323-32.
O'Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ. Nonmotor symptoms as presenting complaints in Parkinson's disease: A clinicopathological study. Mov Disord. 2008;23(1):101-6
Parkinson J. An essay on the shaking palsy (reprint of monograph published by Sherwood, Neely, and Jones, London, 1817). J Neuropsychiatry Clin Neurosci. 2002;14(2):223-36.
Kaufmann H, Goldstein DS. Autonomic dysfunction in Parkinson. Elsevier; 2013.
Khoo TK, Yarnall AJ, Duncan GW, Coleman S, O'Brien JT, Brooks DJ, Barker RA, Burn DJ. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology. 2013;80(3):276-81.
Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci Basic Clin. 2011;161(1-2):46-8.
Velseboer DC, de Haan RJ, Wieling W, Goldstein DS, de Biea RMA. Prevalence of orthostatic hypotension in Parkinson's disease: A systematic review and meta-analysis. Parkinsonism Relat Disord. 2011;17(10):724-9.
Martignoni E, Tassorelli C, Nappi G. Cardiovascular dysautonomia as a cause of falls in Parkinson's disease. Parkinsonism Relat Disord. 2006;12(4):195-204.
Jansen RW, Lipsitz LA. Postprandial hypotension: epidemiology, pathophysiology, and clinical management. Ann Intern Med. 2013;122(4):286-95.
Suárez-Moro R, Castaño-García B. (Cardiovascular disorders in Parkinson's disease). Rev Neurol. 2010;50(Supl. 2):S59-63.
Poon IO, Braun U. High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther. 2005;30(2):173-8.
Bouvette CM, McPhee BR, Opfer-Gehrking TL, Low PA. Role of physical countermaneuvers in the management of orthostatic hypotension: efficacy and biofeedback augmentation. Mayo Clin Proc. 1996;71(9):847-53.
Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, Weintraub D, Sampaio C. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review Mov Disord. 2019;34(2):180-198.
Arbique D, Cheek D, Welliver M, Vongpatanasin W. Management of neurogenic orthostatic hypotension. J Am Med Dir Assoc. 2014;15(4):234-9.
Schoffer KL, Henderson RD, O'Maley K, O'Sullivan JD. Non-pharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord. 2017; 22(11):1543-9.
Ziemssen T, Reichmann H. Treatment of dysautonomia in extrapyramidal disorders. Ther Adv Neurol Disord. 2010;3(1):53-67.
Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, Rubin M, Fouad-Tarazi FM. Neurogenic orthostatic hypotension: A double-blind, placebo-controlled study with midodrine. Am J Med. 1993;95(1):38-48.
Matthias CJ, Fosbraey P, da Costa DF, Thornley A, Bannister R. The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. BMJ. 1986; 293(6543):353-4.
Suchowersky O, Furtado S, Rohs G. Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson's disease. Mov Disord. 1995;10(3):337-40.
Singer W, Sandroni P, Opfer-Gehrking TL, Suarez GA, Klein CM, Hines S, O'Brien PC, Slezak J, Low PA. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol. 2006;63(4):513-8.
Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord. 2011;26(Supl. 3):S42-S80.
Jang W, Park J, Shin KJ, Kim JS, Kim JS, Youn J, Cho JW Oh E, Ahn JY, Oh KW, Kim HT. Safety and efficacy of recombinant human erythropoietin treatment of non-motor symptoms in Parkinson's disease. J Neurol Sci. 2014;337(1-2):47-54.
Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S, Hewitt LA, et al. Droxidopa for neurogenic orthostatic hypotension: A randomized, placebo-controlled, phase 3 trial. Neurology. 2014;83(4):328-35.
Goldstein DS, Pechnik S, Holmes C, Eldadah B, Sharabi Y Association between supine hypertension and ortho-static hypotension in autonomic failure. Hypertension. 2003;42(2):136-42.
Friedrich C, Rüdiger H, Schmidt C, Herting B, Prieur S, Jung-hanns S, Schweitzer K, Globas C, Schõls L, Berg D, Reichmann H, Ziemssen T. Baroreflex sensitivity and power spectral analysis during autonomic testing in different extrapyramidal syndromes. Mov Disord. 2010;25(3):315-24.
Shibao C, Gamboa A, Diedrich A, Biaggioni I. Management of hypertension in the setting of autonomic failure. Hypertension. 2005;45(4):469-76.
Nicaretta DH, Rosso AL, De Mattos JP, Maliska C, Costa MMB. Dysphagia and sialorrhea. Arq Gastroenterol. 2013;50(1):42-9.
Arbouw MEL, Movig KL, Koopmann M, Poels PJ, Guchelaar HJ, Egberts TC, Neef C, van Vugt JP. Glycopyrrolate for sialorrhea in Parkinson disease: A randomized, doubleblind, crossover trial. Neurology. 2010;74(15):1203-7.
Pal PK, Calne DB, Calne S, Tsui JKC. Botulinum toxin A as treatment for drooling saliva in PD. Neurology. 2000;54(1):244-7.
Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Botulinum toxin type A for drooling in Parkinson's disease: A double-blind, randomized, placebo-controlled study. Mov Disord. 2006;21(5):704-7.
Edwards LL, Pfeiffer RF, Quigley EMM, Hofman R, Balluff M. Gastrointestinal symptoms in Parkinson's disease. Mov Disord. 1991;6(2):151-6.
González-Fernández J, Prieto-Albin R, Velasco-Palacios L, Jorge-Roldán S, Cubo-Delgado E. Trastornos digestivos en la enfermedad de Parkinson: disfagia y sialorrea. Rev Neurol. 2010;50(Supl. 2):51-4.
Tumilasci OR, Cersósimo MG, Belforte JE, Micheli FE, Benar-roch EE, Pazo JH. Quantitative study of salivary secretion in Parkinson's disease. Mov Disord. 2006;21(5):660-7.
Heetun ZS, Quigley EMM. Gastroparesis and Parkinson's disease: A systematic review. Parkinsonism Relat Disord. 2012;18(5):433-40.
Marrinan S, Emmanuel AV, Burn DJ. Delayed gastric emptying in Parkinson's disease. Mov Disord. 2014;29(1):23-32.
Pérez-Macho L, Borja-Andrés S. Trastornos digestivos en la enfermedad de Parkinson: atonía gástrica, malabsorción y estreñimiento. Rev Neurol. 2010;50(Supl. 2):55-58.
Agencia Española de Medicamentos y Productos Sanitarios. Domperidona y riesgo cardiaco: restricciones en las condiciones de autorización. 2014. www.aemps.gob.es/informa/nota-sInformativas/medicamentosUsoHumano/seguridad/2014/ docs/NI-MUH_FV_04-2014-domperidona.pdf
Arnold G, Schwarz J, Macher C, Oertel WH. Domperidone is superior to ondansetron in acute apomorphine challenge in previously untreated parkinsonian patients - A double blind study. Parkinsonism Relat Disord. 1997;3(4):191-3.
DiBaise JK, Quigley EM. Efficacy of prolonged administration as, of intravenous erythromycin in an ambulatory setting experience, treatment of severe gastroparesis: one center's. J Clin Gastroenterol. 1999;28(2):131-4.
Zangaglia R, Martignoni E, Glorioso M, Ossola M, Riboldazzi G, Calandrella D, Brunetti G, Pacchetti C. Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study. Mov Disord. 2007;22(9):1239-44.
Araki KS, Kitahara M, Oida T. Voiding dysfunction and Parkinson's disease: urodynamic abnormalities and urinary symptoms. J Urol. 2000;164(5):1640-3.
Vázquez-Sánchez F, Rodríguez-Martínez E, Arés-Luque A. Trastornos urinarios, disfunción sexual e hipersexualidad en la enfermedad de Parkinson. Rev Neurol. 2010;50(Supl. 2):27-31.
Karsenty G, Corcos J, Schurch B, Ruffion A, Chartier-Kastler E. Pharmacological treatment of neurogenic detrusor hyper-activity: intradetrusor botulinum toxin a injections. Prog Urol. 2007;17(3):568-75.
Hobson P, Islam W, Roberts S, Adhiyman V, Meara J. The risk of bladder and autonomic dysfunction in a community cohort of Parkinson's disease patients and normal controls. Parkinsonism Relat Disord. 2003;10(2):67-71.
Bronner G, Vodusek DB. Management of sexual dysfunction in Parkinson's disease. Ther Adv Neurol Disord. 2011;4(6):375-83.
Raffaele R, Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease. Eur Urol. 2002;41(4):382-6.
Swinn L, Schrag A, Viswanathan R, Bloem BR, Lees A, Quinn N. Sweating dysfunction in Parkinson's disease. 2003;18(12):1459-63.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.